TLX101
Glioblastoma Therapy
Key Facts
Indication
Glioblastoma Therapy
Phase
Phase 1
Status
Active/LTFU (IPAX-1)
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals is a global leader in radiopharmaceuticals, focusing on theranostics—a combined diagnostic and therapeutic approach for cancer. The company has achieved commercial success with its FDA-approved prostate cancer imaging agent, Illuccix®, and is advancing a deep clinical pipeline targeting renal, brain, and other cancers. With a vertically integrated platform spanning discovery to commercialization, Telix is strategically positioned to capture significant value in the high-growth precision oncology market.
View full company profile